Attached files
| file | filename |
|---|---|
| EX-21.1 - EX-21.1 - NRX Pharmaceuticals, Inc. | d57577dex211.htm |
| EX-10.34 - EX-10.34 - NRX Pharmaceuticals, Inc. | d57577dex1034.htm |
| EX-10.33 - EX-10.33 - NRX Pharmaceuticals, Inc. | d57577dex1033.htm |
| EX-10.9 - EX-10.9 - NRX Pharmaceuticals, Inc. | d57577dex109.htm |
| EX-10.8 - EX-10.8 - NRX Pharmaceuticals, Inc. | d57577dex108.htm |
| EX-10.7 - EX-10.7 - NRX Pharmaceuticals, Inc. | d57577dex107.htm |
| EX-10.6 - EX-10.6 - NRX Pharmaceuticals, Inc. | d57577dex106.htm |
| EX-3.2 - EX-3.2 - NRX Pharmaceuticals, Inc. | d57577dex32.htm |
| EX-3.1 - EX-3.1 - NRX Pharmaceuticals, Inc. | d57577dex31.htm |
| 8-K - FORM 8-K - NRX Pharmaceuticals, Inc. | d57577d8k.htm |
Exhibit 16.1
May 28, 2021
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read the statements made by NRX Pharmaceuticals, Inc. under Item 4.01 of its Form 8-K dated May 28, 2021. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of NRX Pharmaceuticals, Inc. (formerly known as Big Rock Partners Acquisition Corp.) contained therein.
| Very truly yours, |
| Marcum LLP |
|
| San Francisco, CA May 28, 2021 |
